Galectin Therapeutics earnings were -$45.3M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest GALT earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$9.6M, down 20.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GALT reported annual earnings of -$47.2M, with 5.3% growth.
Galectin Therapeutics Earnings Reports & History FAQ
What were Galectin Therapeutics's earnings last quarter?
On GALT's earnings call on Invalid Date, Galectin Therapeutics (NASDAQ: GALT) reported Q1 2025 earnings per share (EPS) of -$0.15, up 21.05% year over year. Total GALT earnings for the quarter were -$9.61 million. In the same quarter last year, Galectin Therapeutics's earnings per share (EPS) was -$0.19.
Is Galectin Therapeutics profitable or losing money?
As of the last Galectin Therapeutics earnings report, Galectin Therapeutics is currently losing money. Galectin Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$45.19 million, a 1.21% increase year over year.
What was GALT's earnings growth in the past year?
As of Galectin Therapeutics's earnings date in Invalid Date, Galectin Therapeutics's earnings has grown year over year. GALT earnings in the past year totalled -$45.31 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.